The BZW2 Knockout HeLa Polyclonal Cells comprise a population of polyclonal HeLa cells with CRISPR/Cas9-mediated disruption of the BZW2 gene, providing a loss-of-function model for studying BZW2-dependent translational control and oncogenic signaling. This polyclonal knockout product offers a heterogeneous gene-edited population, enabling robust assessment of BZW2 function without clonal selection biases.
Derived from the HeLa cervical adenocarcinoma cell line, these cells retain the HPV18-positive, immortalized, and aneuploid characteristics of the parental line, making them a widely used model for cancer biology and drug screening. The epithelial origin and established tumorigenic properties of HeLa cells provide a relevant background for investigating BZW2’s role in cervical and other epithelial cancers.
BZW2 functions as an eIF5-mimic translation regulator that promotes global protein synthesis and mTORC1 signaling. It is activated downstream of EGFR signaling, amino acid availability, ER stress, and the oncogene c-MYC. Mechanistically, BZW2 interacts with components of the eIF2 and eIF3 complexes, as well as eIF5, eIF2B, and ribosomes, to facilitate translation initiation. This enhances mTORC1 activity, leading to increased phosphorylation of downstream effectors S6K and 4E-BP1, and elevated expression of cyclin D1. Concurrently, BZW2 modulates the integrated stress response by repressing ATF4 translation, thereby suppressing stress-induced apoptosis. The knockout of BZW2 disrupts this signaling axis, impairing mTOR-driven anabolic processes and sensitizing cells to stress-mediated death.
In the HeLa cervical adenocarcinoma context, BZW2 knockout cells model the consequences of disrupted translation regulation and diminished mTOR signaling in an HPV-positive cancer background. This system is particularly valuable for dissecting how BZW2 contributes to uncontrolled proliferation and tumorigenesis, and for evaluating the therapeutic potential of targeting BZW2 in malignancies such as cervical, hepatocellular, colorectal, and breast cancers. The polyclonal nature allows observation of population-level responses to gene loss, reflecting the heterogeneity of tumor cell populations in vivo.
Researchers can employ these cells for a variety of applications, including western blot analysis of phospho-S6K and phospho-4E-BP1 to monitor mTOR activity, RT-qPCR quantification of cyclin D1 and ATF4 expression, and polysome profiling to assess translation efficiency. Functional assays for cell proliferation (MTT/CCK-8), migration, and invasion using Transwell systems are complemented by apoptosis detection via Annexin V/PI staining. Additionally, these cells serve as a platform for screening protein synthesis inhibitors and testing sensitivity to mTOR pathway therapeutics. For more information, please contact Ascent Research.
